← All trials
NCT06044337
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 3, 2023
- Primary completion
- Jun 26, 2029
- Completion date
- Dec 11, 2029
- First posted
- Sep 21, 2023
- Last posted
- Nov 21, 2023
- Enrollment
- 322
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.